Bone marrow mononuclear cells from patients in another phase I study of ivosidenib in advanced hematologic malignancies were assessed for mutant IDH1 variant allele frequency to assess the depth of mIDH1 clearance [116]. Here, IDH1 is linked to hematologic disorder.